ORIENT PHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.2 TWD | -9.19% |
|
-10.00% | +26.00% |
| 15/04 | Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,446 | 2,266 | 2,721 | 3,497 | 3,908 | 4,461 |
| Enterprise Value (EV) 1 | 2,464 | 2,575 | 2,854 | 3,760 | 4,319 | 5,064 |
| P/E ratio | -15.3 x | -11.3 x | -14.4 x | -34.1 x | -136 x | 200 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 9.08 x | 6.41 x | 6.6 x | 7.55 x | 7.64 x | 5.01 x |
| EV / Revenue | 9.14 x | 7.28 x | 6.93 x | 8.12 x | 8.44 x | 5.69 x |
| EV / EBITDA | -12.7 x | -17.1 x | -25 x | -45.7 x | 347 x | 36.4 x |
| EV / FCF | -19.5 x | -27.8 x | -17.7 x | -37.1 x | -387 x | -26.9 x |
| FCF Yield | -5.14% | -3.59% | -5.64% | -2.69% | -0.26% | -3.71% |
| Price to Book | 2.08 x | 2.3 x | 2.24 x | 3.13 x | 3.59 x | 2.67 x |
| Nbr of stocks (in thousands) | 1,56,023 | 1,56,244 | 1,87,013 | 1,87,003 | 1,87,003 | 2,23,035 |
| Reference price 2 | 15.68 | 14.50 | 14.55 | 18.70 | 20.90 | 20.00 |
| Announcement Date | 29/04/19 | 27/04/20 | 16/04/21 | 31/03/22 | 17/03/23 | 15/04/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 269.5 | 353.5 | 412 | 463.3 | 511.9 | 889.9 |
| EBITDA 1 | -194.1 | -150.7 | -114.3 | -82.3 | 12.43 | 139 |
| EBIT 1 | -249.1 | -205.4 | -166.8 | -133.5 | -41.74 | 24.32 |
| Operating Margin | -92.4% | -58.09% | -40.47% | -28.81% | -8.15% | 2.73% |
| Earnings before Tax (EBT) 1 | -244.7 | -202.4 | -165.6 | -110.1 | -41.11 | 22.92 |
| Net income 1 | -160.1 | -201 | -171.4 | -102.7 | -28.76 | 22.29 |
| Net margin | -59.4% | -56.86% | -41.59% | -22.15% | -5.62% | 2.5% |
| EPS 2 | -1.028 | -1.288 | -1.012 | -0.5489 | -0.1538 | 0.0999 |
| Free Cash Flow 1 | -126.6 | -92.56 | -160.9 | -101.3 | -11.17 | -188 |
| FCF margin | -46.97% | -26.18% | -39.05% | -21.87% | -2.18% | -21.13% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/04/19 | 27/04/20 | 16/04/21 | 31/03/22 | 17/03/23 | 15/04/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 18 | 309 | 133 | 263 | 411 | 604 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.0929 x | -2.052 x | -1.166 x | -3.199 x | 33.06 x | 4.345 x |
| Free Cash Flow 1 | -127 | -92.6 | -161 | -101 | -11.2 | -188 |
| ROE (net income / shareholders' equity) | -12.8% | -18.6% | -15.6% | -8.8% | -2.61% | 1.61% |
| ROA (Net income/ Total Assets) | -9.79% | -8.32% | -6.3% | -4.76% | -1.44% | 0.69% |
| Assets 1 | 1,636 | 2,415 | 2,719 | 2,158 | 1,991 | 3,234 |
| Book Value Per Share 2 | 7.540 | 6.310 | 6.510 | 5.970 | 5.830 | 7.490 |
| Cash Flow per Share 2 | 0.3700 | 0.2400 | 0.2700 | 0.7000 | 0.4100 | 0.3700 |
| Capex 1 | 20.2 | 24 | 74.3 | 66.5 | 28.4 | 54.1 |
| Capex / Sales | 7.51% | 6.8% | 18.04% | 14.36% | 5.55% | 6.08% |
| Announcement Date | 29/04/19 | 27/04/20 | 16/04/21 | 31/03/22 | 17/03/23 | 15/04/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +26.00% | 173M | |
| +29.98% | 682B | |
| +32.45% | 586B | |
| -3.52% | 364B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.83% | 240B | |
| +9.57% | 209B | |
| -8.79% | 203B | |
| +7.09% | 165B |
- Stock Market
- Equities
- 4166 Stock
- Financials Orient Pharma Co., Ltd.